• Mashup Score: 2
    Patient first; person first - 7 month(s) ago

    A cancer patient. A cancer case. Common terms, but ones that can have a great impact on patients and their mental health. By using disease-first language such as this, one can dehumanise the patient, equating them with their disease rather than referring to them as an individual. Dehumanising and stigma-laden terminology is rife in medicine, with oncology being no exception, and blame-ridden language is too often used when referring to people at risk for or who have cancer. Although not coming from a place of malice, or indeed reflective of an intentional effort to offend, these phrases are typically used as shorthand in an effort to aid communication, but the lack of empathy and awareness that accompanies the use of such language could also be linked with apathetic attitudes.

    Source: www.thelancet.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of crisbergerot
      crisbergerot

      RT @MDRoeland: THIS - exactly. Patient first; person first - The Lancet Oncology @ASCO #pallonc #hpm https://t.co/sVFJuOx2Ir

  • Mashup Score: 0
    Geriatric Assessments in Older Adults With Cancer - 7 month(s) ago

    This JAMA Oncology Patient Page describes the geriatric assessment used by clinicians to evaluate the health of older adults with cancer.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of RyanNipp
      RyanNipp

      Geriatric Assessments in Older Adults With #Cancer. https://t.co/mGxY9cJHHe @JAMA_current @JAMAOnc @myCARG @MazieTsangMD #GeriOnc #PallOnc #Geriatrics https://t.co/CvAyqIxvFf

  • Mashup Score: 0
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649 - 8 month(s) ago

    PURPOSE In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non–human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs). METHODS In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≄5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≄1 postbaseline

    Source: ascopubs.org
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of RyanNipp
      RyanNipp

      Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction #Cancer or Esophageal Adenocarcinoma From CheckMate 649. https://t.co/uE6x5PirHa @ASCO @JCO_ASCO @JCOOP_ASCO #Immunotherapy #PallOnc https://t.co/WHz7MwpRXT

Load More